Last updated: May 24, 2026
VYLEESI (bremelanotide) autoinjector supply chain involves a drug product manufacturer for the peptide and a device supply/manufacturing chain for the autoinjector. The supplier set is determined by the FDA-listed manufacturers on the VYLEESI label and the device/combination product manufacturing records associated with the autoinjector.
What companies supply VYLEESI autoinjector drug product and device components?
VYLEESI is a bremelanotide injection supplied as an autoinjector, making it a combination between the drug substance/drug product and a delivery device. “Suppliers” in practice fall into two buckets: (1) FDA-listed drug product manufacturers and (2) autoinjector device OEM or device manufacturing partners.
Who is listed as the drug product manufacturer for VYLEESI?
The FDA label’s “Manufactured for” and “Distributed by” lines identify the marketing authorization holder and the drug product manufacturer(s). These are the controlling suppliers for regulatory submissions, GMP release testing, and commercial scale manufacturing.
Who supplies the autoinjector device for VYLEESI?
The autoinjector device supply is governed by the combination product’s device master record and the autoinjector’s manufacturing/OEM chain. The practical suppliers are the device manufacturer and the device component makers (needle, spring, housing, trigger mechanism, cartridge).
What is the Orange Book status of VYLEESI and does it affect supplier choices?
VYLEESI is a brand-name prescription drug; the availability of an Orange Book listing determines whether generic competition can alter sourcing. Orange Book listings can signal exclusivity but do not directly identify device/OEM suppliers. They do, however, affect procurement risk because generic entry can change bulk demand and constrain supply allocation for branded product manufacturing.
What exclusivity and patent posture does VYLEESI have that impacts supply continuity?
Patent and exclusivity status can influence whether additional manufacturers are added before launch for a new formulation or after lifecycle changes. For suppliers, the main impact is whether the brand expands manufacturing redundancy or keeps single-site supply for cost control.
Which suppliers manufacture bremelanotide injection for VYLEESI?
Because bremelanotide is a synthetic peptide, supplier selection typically includes:
- peptide drug substance manufacturers (synthetic/peptide assembly and purification)
- sterile drug product manufacturers (formulation, fill-finish, sterility assurance)
- combination product assembly sites (joining drug fill and device)
For VYLEESI, the named regulatory entities on the product label and FDA submissions define the controlling manufacturing nodes for commercial supply.
How does the VYLEESI autoinjector supply chain work (drug fill-finish vs device assembly)?
A typical autoinjector supply chain includes:
- sterile drug product fill into the device reservoir or cartridge
- device assembly (needle attachment, activation mechanism)
- final combination packaging and labeling under GMP
For VYLEESI, the supplier model depends on whether the final filled device is produced at a single integrated site or assembled via multi-site manufacturing.
What manufacturing barriers can constrain autoinjector supply?
- device part availability (needle sets, spring/trigger mechanisms)
- sterile fill-finish capacity
- validation of system compatibility (protein/peptide stability in device environment, extractables/leachables)
- combination product regulatory change control
Are there alternative device suppliers or is VYLEESI a single-OEM autoinjector?
For autoinjectors, device OEM changes are usually controlled by comparability testing and regulatory documentation. If VYLEESI uses a single autoinjector platform, the supplier set tends to be stable. If the brand has performed device life-cycle changes (e.g., needle geometry or activation force), supply can involve at least two device supply chains, with qualification documented in regulatory change packages.
What generic entry risks exist for VYLEESI that could change supplier allocations?
Generic entry risk is driven by Orange Book status, patent landscape, and exclusivity expirations. Supplier allocations can shift if demand changes from branded supply to generic demand. For autoinjectors, generics may require:
- compatible dosing and delivery performance
- device design comparability
- NDA/ANDA manufacturing qualification
That can change supplier leverage and manufacturing economics even when the labeled dose remains the same.
Key Takeaways
- VYLEESI supply is split between drug product manufacturers (sterile bremelanotide injection fill-finish and release) and autoinjector device suppliers (OEM/device manufacturing for the delivery platform).
- The controlling “supplier” names for contracting and regulatory purposes are those listed on the VYLEESI label for manufacturing and distribution.
- Autoinjector supply continuity depends on device component availability, sterile fill-finish capacity, and combination product validation.
FAQs
1) Who is the marketing authorization holder for VYLEESI?
The marketing authorization holder is the branded label entity shown on the VYLEESI prescribing information.
2) Are device components like needles and cartridges supplied by the same OEM as the autoinjector body?
Autoinjector supply chains typically include specialized component makers for needles and other precision parts, with final assembly tied to the device OEM or assembly site.
3) Can VYLEESI be manufactured at multiple sites in parallel?
Brands often qualify backup manufacturing sites or multiple device assembly sources, but the definitive answer is in FDA manufacturing/labeling information and change history.
4) Do exclusivity and patents for bremelanotide affect device supplier contracts?
They mainly affect commercial demand stability and whether the brand adds manufacturing redundancy ahead of loss of exclusivity.
5) What documentation governs changes to the VYLEESI autoinjector design?
Combination product change control under GMP and regulatory comparability requirements governs device design updates, including compatibility, extractables/leachables, and performance.
References
- U.S. Food and Drug Administration. VYLEESI (bremelanotide) Prescribing Information and label manufacturing/distribution information. FDA label repository.
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
